Background : Pathological complete response is a predictor of favorable clinical outcome in patients with tripl-negative breast cancer. Over the last years there was an increasing interest to the search for predictive markers of tumor response to neoadjuvant chemotherapy (NACH). The purpose of the study is to assess predictive markers: cytokeratin 5/6, epidermal growth factor receptor (EGF1) and proliferation marker Ki-67 in patients with basal-like tripl-negative breast cancer. Materials and methods : The study included 44 patients with basal-like tripl-negative breast cancer, who received 2–4 courses of NACH with FAC and CAX regimens. Estrogen and progesterone receptors, Her-2/neu, the levels of proliferative activity of Ki-67, CK 5/6 and EGFR1 were determined in all breast cancer biopsies. Response to NACH was assessed using RECIST scale. Results . Pathological complete response was observed in 69 % of breast cancer patients, who had only EGFR1expression in tumor tissue (р=0.01). The best response was noted at high proliferative activity of tumor cells (90 %, р=0.0006) and when using CAX regimen (81 %, р=0.004). The model of logistic regression enables prediction of pathological complete response with high rates of sensitivity (82 %) and specificity (67 %). Conclusion . The results obtained indicate that the studied markers can be used as predictors of clinical outcome and the devised model of logistic regression can be used to predict the chemotherapy response of breast cancer based on clinical pathological variables.
分享
引用
